Lorazepam

Hikma Pharmaceuticals USA Inc. initiated a Class II recall for 382,775 vials of Lorazepam Injection due to out-of-specification impurities. This voluntary, firm-initiated action, impacting nationwide U.S. distribution, signals critical quality control challenges at their Berkeley Heights, NJ facility. Procurement and regulatory teams must assess immediate supply chain risks and re-evaluate supplier qualification for this essential benzodiazepine.

The Harvard Drug Group LLC dba Major Pharmaceuticals initiated a Class II recall of Lorazepam Tablets, USP, 0.5mg, due to sub-potency and impurity failures. This event highlights critical quality control gaps within the pharmaceutical supply chain, demanding immediate action from procurement and regulatory teams to ensure supply continuity and patient safety for this essential benzodiazepine.